Osteogenic growth peptide (OGP), a selective CB2 agonist, reduces cancer progression in two models of colon cancer and one model of breast cancer in mice by modulating immune responses. Human genetic data supports the role of CB2 in tumor immunology.

UNMET NEED
Colon carcinoma and breast cancer are prevalent solid tumors with limited therapies and high levels of relapse.

OUR SOLUTION
Osteogenic growth peptide (OGP), a selective CB2 agonist, modulates immune responses to reduce tumor growth in ApcMin/+ (genetic model) and in AOM/DSS-treated (chemically-induced) mice as well as in a model of breast cancer.

KEY ADVANTAGES 
• Increases survival
• Reduces tumor number and size
• Decreases tumor-promoting myeloid cells and alleviates the immunosuppressive tumor microenvironment (TME)
• Enhances anti-tumor CD8+ T cells
• Supported by human CNR2 genetic data

APPLICATIONS
• Colon carcinoma and breast cancer therapy and prevention
• Potential for other solid cancers with immunosuppressive TME

STAGE OF DEVELOPMENT
• Preclinical proof-of-concept in mice and in cell cultures
• Human genetic associations

IP STATUS
PCT/IL2025/050869

PUBLICATIONS
Nature Oncogene, 2025